Patient and Family Resources
How to get more information and support on your way to recovery
Depression is a widely recognized disease that affects over 20 million Americans5. As physicians and scientists gain a deeper understanding of this disease, more and more insights into treatment are becoming available.
Information Links: In this section of the Marplan® (isocarboxazid) Tablets website you'll find resource listings that will take you directly to the websites that other experts have created to provide you with additional in-depth information about depression, psychotherapy, and antidepressant medications. Just click on a link and you'll be taken to those specialized sites.
Advocacy Group Links: We've also provided links to support groups & advocacy organizations whose members are people with depression, their families, and their caregivers—as well as some important healthcare professionals who are interested in helping patients deal successfully with their disease. These groups can provide you with more than information. They can share personal insights into how members and families have been able to successfully cope with challenges very similar to your own. Many of these websites also offer "member hotlines" or local chapters that can provide one-on-one support.
Please click here to review the Marplan® (isocarboxazid) Tablets references.
Please see Full Prescribing Information including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO Inhibitors are contraindicated with certain drugs. Potential hypertensive crises may occur with foods that contain tyramine. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of treatment.
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Marplan® (isocarboxazid) Tablets or any other antidepressant in a child, adolescent or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Marplan® (isocarboxazid) Tablets is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use).
Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials.
